Dr. West on NSCLC Afatinib and Cetuximab Combination

H. Jack West, MD
Published: Thursday, Jul 07, 2011

H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington discusses some of the results from the phase II trial combining two therapies, afatinib and cetuximab, in patients with T790M mutated as a mechanism of resistance in non-small cell lung cancer (NSCLC). He describes that the benefit not only helped T790M patients but also those without the mutation.
H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington discusses some of the results from the phase II trial combining two therapies, afatinib and cetuximab, in patients with T790M mutated as a mechanism of resistance in non-small cell lung cancer (NSCLC). He describes that the benefit not only helped T790M patients but also those without the mutation.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x